Clinect
Privately held: no public share price · Australia
Assets
(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Approved | TRPV1 (transient receptor potential vanilloid 1) channelSmall molecule | Diabetic Peripheral Neuropathic Pain Diabetic Peripheral Neuropathy |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
27 October 2026PresentationCapsaicin (Qutenza)Phase III RISE results at IASP 2026: one of the primary endpoints met (average pain intensity, weeks 2-12)
Financial reports
No financial reports recorded.